167 related articles for article (PubMed ID: 37818225)
1. Legacy perfluoro-alkyl substances impair LDL-cholesterol uptake independently from PCSK9-function.
Sabovic I; Lupo MG; Rossi I; Pedrucci F; Di Nisio A; Dall'Acqua S; Ferri N; Ferlin A; Foresta C; De Toni L
Toxicol Rep; 2023 Dec; 11():288-294. PubMed ID: 37818225
[TBL] [Abstract][Full Text] [Related]
2. Comparative Evaluation of the Effects of Legacy and New Generation Perfluoralkyl Substances (PFAS) on Thyroid Cells
De Toni L; Di Nisio A; Rocca MS; Pedrucci F; Garolla A; Dall'Acqua S; Guidolin D; Ferlin A; Foresta C
Front Endocrinol (Lausanne); 2022; 13():915096. PubMed ID: 35813651
[TBL] [Abstract][Full Text] [Related]
3. The association between perfluoroalkyl substances and lipid profile in exposed pregnant women in the Veneto region, Italy.
Dalla Zuanna T; Savitz DA; Barbieri G; Pitter G; Zare Jeddi M; Daprà F; Fabricio ASC; Russo F; Fletcher T; Canova C
Ecotoxicol Environ Saf; 2021 Feb; 209():111805. PubMed ID: 33360787
[TBL] [Abstract][Full Text] [Related]
4. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
5. Increased Cardiovascular Risk Associated with Chemical Sensitivity to Perfluoro-Octanoic Acid: Role of Impaired Platelet Aggregation.
De Toni L; Radu CM; Sabovic I; Di Nisio A; Dall'Acqua S; Guidolin D; Spampinato S; Campello E; Simioni P; Foresta C
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936344
[TBL] [Abstract][Full Text] [Related]
6. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
7. Exposure to Perfluoro-Octanoic Acid Associated With Upstream Uncoupling of the Insulin Signaling in Human Hepatocyte Cell Line.
De Toni L; Di Nisio A; Rocca MS; Guidolin D; Della Marina A; Bertazza L; Sut S; Purpura E; Pannella M; Garolla A; Foresta C
Front Endocrinol (Lausanne); 2021; 12():632927. PubMed ID: 34539566
[TBL] [Abstract][Full Text] [Related]
8. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
9. The new generation PFAS C6O4 does not produce adverse effects on thyroid cells in vitro.
Coperchini F; Croce L; Pignatti P; Ricci G; Gangemi D; Magri F; Imbriani M; Rotondi M; Chiovato L
J Endocrinol Invest; 2021 Aug; 44(8):1625-1635. PubMed ID: 33315184
[TBL] [Abstract][Full Text] [Related]
10. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
11. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y
J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555
[TBL] [Abstract][Full Text] [Related]
12. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
[TBL] [Abstract][Full Text] [Related]
13. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
14. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins.
Kwakernaak AJ; Lambert G; Dullaart RP
Clin Biochem; 2014 May; 47(7-8):679-82. PubMed ID: 24680982
[TBL] [Abstract][Full Text] [Related]
15. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
[TBL] [Abstract][Full Text] [Related]
16. Proprotein Convertase Subtilisin Kexin 9 (PCSK9) and nonHDL particles rise during normal pregnancy and differ by BMI.
Wild RA; Weedin E; Cox K; Zhao YD; Wrenn DS; Lopez D; Wooten CJ; Melendez QM; Myers D; Hansen KR
J Clin Lipidol; 2022; 16(4):483-490. PubMed ID: 35717446
[TBL] [Abstract][Full Text] [Related]
17. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.
Alborn WE; Cao G; Careskey HE; Qian YW; Subramaniam DR; Davies J; Conner EM; Konrad RJ
Clin Chem; 2007 Oct; 53(10):1814-9. PubMed ID: 17702855
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia.
Wu C; Xi C; Tong J; Zhao J; Jiang H; Wang J; Wang Y; Liu H
Acta Pharm Sin B; 2019 Nov; 9(6):1216-1230. PubMed ID: 31867167
[TBL] [Abstract][Full Text] [Related]
19. Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease.
Nozue T; Hattori H; Ogawa K; Kujiraoka T; Iwasaki T; Hirano T; Michishita I
Lipids Health Dis; 2016 Sep; 15(1):165. PubMed ID: 27658826
[TBL] [Abstract][Full Text] [Related]
20. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
